ATE332138T1 - Flibanserin zur behandlung extrapyramidaler bewegungsstörungen - Google Patents

Flibanserin zur behandlung extrapyramidaler bewegungsstörungen

Info

Publication number: ATE332138T1
Authority: AT; Austria
Prior art keywords: parkinson; disease; treatment; extrapyramidal; idiopathic
Prior art date: 2001-05-11

Application number

AT01111195T

Other languages

English (en)

Inventor

Juergen K Dr Beck

Original Assignee

Juergen K Dr Beck

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-11

Filing date

2001-05-11

Publication date

2006-07-15

2001-05-11 Application filed by Juergen K Dr Beck filed Critical Juergen K Dr Beck

2006-07-15 Application granted granted Critical

2006-07-15 Publication of ATE332138T1 publication Critical patent/ATE332138T1/de

Links

PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 title 1
229960002053 flibanserin Drugs 0.000 title 1
208000018737 Parkinson disease Diseases 0.000 abstract 3
229940035678 anti-parkinson drug Drugs 0.000 abstract 3
239000000939 antiparkinson agent Substances 0.000 abstract 3
208000016285 Movement disease Diseases 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 2
MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
208000012661 Dyskinesia Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000007774 longterm Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT01111195T 2001-05-11 2001-05-11 Flibanserin zur behandlung extrapyramidaler bewegungsstörungen ATE332138T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01111195A EP1256343B1 (de)	2001-05-11	2001-05-11	Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen

Publications (1)

Publication Number	Publication Date
ATE332138T1 true ATE332138T1 (de)	2006-07-15

Family

ID=8177363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01111195T ATE332138T1 (de)	2001-05-11	2001-05-11	Flibanserin zur behandlung extrapyramidaler bewegungsstörungen

Country Status (12)

Country	Link
US (1)	US8030314B2 (de)
EP (1)	EP1256343B1 (de)
JP (1)	JP4634008B2 (de)
AT (1)	ATE332138T1 (de)
AU (1)	AU2002310813B2 (de)
CA (1)	CA2444062C (de)
CY (1)	CY1105648T1 (de)
DE (1)	DE60121301T2 (de)
DK (1)	DK1256343T3 (de)
ES (1)	ES2267627T3 (de)
PT (1)	PT1256343E (de)
WO (1)	WO2002092088A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10053397A1 (de) *	2000-10-20	2002-05-02	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) *	2000-08-24	2005-07-28	Neurobiotec Gmbh	Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) *	2000-12-16	2002-07-04	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US7183410B2 (en) *	2001-08-02	2007-02-27	Bidachem S.P.A.	Stable polymorph of flibanserin
US20030060475A1 (en) *	2001-08-10	2003-03-27	Boehringer Ingelheim Pharma Kg	Method of using flibanserin for neuroprotection
DE10138273A1 (de) *	2001-08-10	2003-02-27	Boehringer Ingelheim Pharma	Arzneimittel mit neuroprotektiver Wirkung
US10675280B2 (en)	2001-10-20	2020-06-09	Sprout Pharmaceuticals, Inc.	Treating sexual desire disorders with flibanserin
UA78974C2 (en)	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
JP2006516549A (ja) *	2002-12-23	2006-07-06	メルクフロストカナダアンドカンパニー	パーキンソン病の治療用医薬組成物及び治療方法
US20050239798A1 (en) *	2004-04-22	2005-10-27	Boehringer Ingelheim Pharmaceuticals, Inc.	Method for the treatment of premenstrual and other female sexual disorders
AU2005235422B2 (en) *	2004-04-22	2011-08-11	Boehringer Ingelheim International Gmbh	New pharmaceutical compositions for the treatment of sexual disorders II
US20060025420A1 (en) *	2004-07-30	2006-02-02	Boehringer Ingelheimn International GmbH	Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) *	2004-09-03	2008-04-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	注意欠如活動過多障害の治療方法
JP2008538741A (ja) *	2005-03-04	2008-11-06	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	鬱病の治療用及び／又は予防用の医薬組成物
EP1858515A2 (de) *	2005-03-04	2007-11-28	Boehringer Ingelheim International Gmbh	Pharmazeutische zusammensetzungen zur behandlung und/oder vorbeugung von mit angstzuständen verbundenen erkrankungen
WO2006096439A2 (en) *	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2608249A1 (en) *	2005-05-06	2006-11-16	Boehringer Ingelheim International Gmbh	Method for the treatment of drug abuse with flibanserin
CA2608713A1 (en) *	2005-05-19	2006-11-23	Boehringer Ingelheim International Gmbh	Method for the treatment of sexual dysfunctions due to medical conditions
WO2006125042A1 (en) *	2005-05-19	2006-11-23	Boehringer Ingelheim International Gmbh	Method for the treatment of drug-induced sexual dysfunction
WO2007014929A1 (en)	2005-08-03	2007-02-08	Boehringer Ingelheim International Gmbh	Use of flibanserin in the treatment of obesity
US7923449B2 (en)	2005-10-29	2011-04-12	Boehringer Ingelheim International Gmbh	Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) *	2005-10-29	2007-05-31	Angelo Ceci	Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) *	2005-11-08	2007-05-10	Stephane Pollentier	Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090023712A1 (en) *	2006-02-18	2009-01-22	Boehringer Ingelheim International Gmbh	Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
US9066903B2 (en)	2006-02-28	2015-06-30	The United States Of America As Represented By The Department Of Veterans Affairs	Pharmacological treatment of Parkinson's disease
DE602007004615D1 (de)	2006-06-30	2010-03-18	Boehringer Ingelheim Pharma	Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
CA2657043A1 (en) *	2006-07-14	2008-01-17	Boehringer Ingelheim International Gmbh	Use of flibanserin for the treatment of sexual disorders in females
KR20090042967A (ko)	2006-08-14	2009-05-04	베링거 인겔하임 인터내셔날 게엠베하	플리반세린 제형 및 이의 제조방법
CL2007002214A1 (es)	2006-08-14	2008-03-07	Boehringer Ingelheim Int	Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
JP5220746B2 (ja)	2006-08-25	2013-06-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	制御放出システム及びその製造方法
ATE524446T1 (de)	2006-12-20	2011-09-15	Boehringer Ingelheim Int	Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
DE102007009264A1 (de) *	2007-02-26	2008-08-28	Ellneuroxx Ltd.	9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen
PE20091188A1 (es)	2007-09-12	2009-08-31	Boehringer Ingelheim Int	Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CA2686480A1 (en) *	2008-12-15	2010-06-15	Boehringer Ingelheim International Gmbh	New salts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2231902T3 (es) *	1996-12-02	2005-05-16	MERCK SHARP & DOHME LTD.	Uso de antagonistas del receptor de nk-1 para el tratamiento de transtornos del movimiento.
GB9706089D0 (en) *	1997-03-24	1997-05-14	Scherer Ltd R P	Pharmaceutical composition
FR2768338B1 (fr) *	1997-09-17	1999-10-15	Synthelabo	Compositions pharmaceutiques contenant un inhibiteur de la monoamine oxydase et leur application en therapeutique

2001
- 2001-05-11 DE DE60121301T patent/DE60121301T2/de not_active Expired - Lifetime
- 2001-05-11 PT PT01111195T patent/PT1256343E/pt unknown
- 2001-05-11 EP EP01111195A patent/EP1256343B1/de not_active Expired - Lifetime
- 2001-05-11 DK DK01111195T patent/DK1256343T3/da active
- 2001-05-11 ES ES01111195T patent/ES2267627T3/es not_active Expired - Lifetime
- 2001-05-11 AT AT01111195T patent/ATE332138T1/de active
2002
- 2002-05-10 JP JP2002589005A patent/JP4634008B2/ja not_active Expired - Fee Related
- 2002-05-10 WO PCT/EP2002/005182 patent/WO2002092088A2/en active Application Filing
- 2002-05-10 US US10/473,525 patent/US8030314B2/en not_active Expired - Fee Related
- 2002-05-10 AU AU2002310813A patent/AU2002310813B2/en not_active Ceased
- 2002-05-10 CA CA2444062A patent/CA2444062C/en not_active Expired - Fee Related
2006
- 2006-10-05 CY CY20061101438T patent/CY1105648T1/el unknown

Also Published As

Publication number	Publication date
EP1256343A1 (de)	2002-11-13
EP1256343B1 (de)	2006-07-05
PT1256343E (pt)	2006-11-30
US20040180904A1 (en)	2004-09-16
ES2267627T3 (es)	2007-03-16
CY1105648T1 (el)	2010-12-22
WO2002092088A3 (en)	2003-01-30
JP4634008B2 (ja)	2011-02-16
DE60121301T2 (de)	2007-07-19
CA2444062A1 (en)	2002-11-21
US8030314B2 (en)	2011-10-04
CA2444062C (en)	2011-02-22
JP2004529175A (ja)	2004-09-24
AU2002310813B2 (en)	2008-04-03
DK1256343T3 (da)	2006-10-30
WO2002092088A2 (en)	2002-11-21
DE60121301D1 (de)	2006-08-17

Legal Events

Date

Code

Title

Description

2007-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1256343

Country of ref document: EP

Publication	Publication Date	Title
ATE332138T1 (de)	2006-07-15	Flibanserin zur behandlung extrapyramidaler bewegungsstörungen
JP4219399B2 (ja)	2009-02-04	分散性錠剤
ATE235895T1 (de)	2003-04-15	Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
CY1109861T1 (el)	2014-09-10	Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
EA200301165A1 (ru)	2004-06-24	Лекарственное средство на основе оксикодона
BR0011867A (pt)	2002-03-05	Preparação farmacêutica de levodopa/carbidopa/entacapona
HUP0402217A2 (hu)	2005-01-28	Platinaszármazékot tartalmazó gyógyászati készítmények
EA200800056A1 (ru)	2008-06-30	Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
HUP0302897A2 (hu)	2003-12-29	Kiváló hatású transzdermális terápiás készítmény a Parkinson-kór kezelésére
DE50005529D1 (de)	2004-04-08	Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60313359D1 (de)	2007-05-31	Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
ATE298324T1 (de)	2005-07-15	Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
HUP0105173A2 (hu)	2003-08-28	Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
EA200600817A1 (ru)	2006-12-29	Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
DE60102590T2 (de)	2005-04-21	Darreichungsformen zur behandlung von oralen mykosen
CA2455621A1 (en)	2003-02-06	Use of (r/s)-(-/+) or (s)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane for the treatment of extrapyramidal movement disorders
NO20061515L (no)	2006-06-06	Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn
RU2002127006A (ru)	2004-03-27	Новое применение (r)-(-)-2-[5-(4-фторофенил)-3-пиридилметиламинометил]-хромана и его физиологически приемлемых солей
CA2429793A1 (en)	2002-06-06	Interferon therapeutic effect enhancer
EA200400348A1 (ru)	2005-04-28	Цисплатиновые составы пониженной токсичности и способы их применения
HUP0402062A2 (hu)	2005-02-28	Alkanoil-L-karnitin alkalmazása merevedési zavar kezelésére és ezt tartalmazó gyógyszerkészítmények
DE602006016168D1 (de)	2010-09-23	1,3,5-triazepin-dionen zur Behandlung von Malaria
ITMI20020872A1 (it)	2003-10-23	Derivati dell'iperforina loro uso e formulazioni che li contengono
DE60202299D1 (de)	2005-01-20	Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
CY1106694T1 (el)	2012-05-23	Σουλφοναμιδια και παραγωγα αυτων που ρυθμιζουν τη δραστικοτητα ενδοθηλινης